Masimo Corporation Reports 8.5% Revenue Growth to $403.6 Million for Quarter Ending April 4, 2026

Masimo Corporation reported its financial results for the quarter ending April 4, 2026, revealing a total revenue of $403.6 million, an increase of 8.5% from $372.0 million in the same period last year. The growth was primarily driven by higher consumables and service revenue, with foreign exchange rate movements contributing an additional $5.6 million to the revenue increase. The company's gross profit for the quarter was $250.8 million, representing a gross margin of 62.1%, slightly down from 62.9% in the prior year, attributed to increased costs from tariffs and production.

Operating expenses rose to $173.4 million, up from $156.0 million, largely due to transaction-related costs associated with the proposed merger with Danaher Corporation, which accounted for approximately $17.9 million. The company reported an operating income of $77.4 million, a slight decrease from $78.0 million in the previous year. Non-operating losses improved to $6.1 million from $9.6 million, reflecting lower interest expenses. The net income for the quarter was $57.1 million, a significant recovery from a loss of $170.7 million in the same quarter last year, which included substantial losses from discontinued operations.

Masimo's operational metrics showed a shipment of approximately 76,800 noninvasive technology boards and instruments, an increase from 72,200 units shipped in the prior year. The company continues to focus on its healthcare segment, which remains its sole reportable segment following the divestiture of its non-healthcare consumer business, completed in September 2025. The company’s cash and cash equivalents stood at $124.6 million, down from $152.3 million at the beginning of the year, while total assets decreased to $1.64 billion from $1.70 billion.

Looking ahead, Masimo is preparing for the completion of its merger with Danaher, which is expected to close later in 2026, pending regulatory approvals and stockholder consent. The merger agreement stipulates that shareholders will receive $180.00 in cash per share. The company anticipates incurring additional costs related to the merger, including financial advisory and legal fees. Despite the challenges posed by market conditions, including inflation and supply chain issues, Masimo remains optimistic about its long-term growth prospects in the healthcare sector, particularly in expanding its patient monitoring technologies and hospital automation solutions.